secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kezar Life Sciences, Inc. (KZR)
CIK:        0001645666
Form:       8-K
Filed at:   2024-10-04T23:59:59+00:00
Accession:  0000950170-24-112969
Event type: regulatory
Sentiment:  negative
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA clinical hold on Kezar's zetomipzomib IND for lupus nephritis after 4 fatal SAEs
--------------------------------------------------------------------------------

- FDA clinical hold on zetomipzomib IND for lupus nephritis after Kezar voluntarily suspended PALIZADE trial enrollment.
- Four Grade 5 (fatal) SAEs in PALIZADE trial (Philippines and Argentina) led to IDMC recommendation for suspension.
- Phase 2a PORTOLA trial for autoimmune hepatitis remains active; no Grade 4 or 5 SAEs observed.
- FDA to provide official clinical hold letter within 30 days; company investigating fatal cases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645666/000095017024112969/0000950170-24-112969-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645666/000095017024112969/kzr-20241004.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-112969

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer